Bladder CancerRIVERSNCT07038928
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
An observational study of Bladder Cancer, run by AstraZeneca at 20 sites in Russia.
Trial summary
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bladder Cancer
- How many people
- 600 participants
- Where
- 20 sitesRussia
- Study dates
- 30 Jun 2025to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Planned study population consists of approximately 600 adult patients with urothelial bladder cancer. Patients who were diagnosed with urothelial bladder cancer and satisfy the additional eligibility criteria as assessed by the investigator will be invited to participate during routine clinical visit. Only patients who will give their written informed consent will be included. Consecutive patients included in the study will form three study cohorts of equal size (around 200 participants each) according to the stages of urothelial bladder cancer at the time of study inclusion: high-risk NMIBC, MIBC, and mBC.
Who may be able to join
- Age ≥ 18 years;
- Signed ICF, including consent for FFPE tumor tissue sample testing;
- Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry;
- For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature:
- T1 tumor
- High grade/G3 tumor
Show all 12Show fewer
- CIS (carcinoma in situ)
- Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point);
- For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry;
- For patients with mBC: mBC diagnosed during 12 months prior to study entry;
- Availability of medical history data;
- Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery.
Who cannot join
- Participation in any interventional trial since the urothelial bladder cancer diagnosis.
Trial locations and contacts
20 sites in 1 country. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
20 sites in 1 country
Russia20 sites, 17 recruiting
- Recruiting
Research Site
Arkhangelsk
- Recruiting
Research Site
Barnaul
- Recruiting
Research Site
Chelyabinsk
- Recruiting
Research Site
Krasnodar
- Recruiting
Research Site
Krasnoyarsk
- Recruiting
Research Site
Makhachkala
- Recruiting
Research Site
Moscow
- Withdrawn
Research Site
Moscow
- Not yet recruiting
Research Site
Moscow
- Recruiting
Research Site
Nizhny Novgorod
- Withdrawn
Research Site
Novosibirsk
- Not yet recruiting
Research Site
Obninsk
- Recruiting
Research Site
Omsk
- Recruiting
Research Site
Saint Petersburg
- Not yet recruiting
Research Site
Saint Petersburg
- Withdrawn
Research Site
Saint Petersburg
- Recruiting
Research Site
Tomsk
- Recruiting
Research Site
Tyumen
- Recruiting
Research Site
Ufa
- Recruiting
Research Site
Yekaterinburg
About this study
Official title: A Multicentre Observational Study on Treatment Approaches and HER2 Positive Status Prevalence in Different Stages of Bladder Cancer and PD-L1-positive Status in Metastatic Bladder Cancer in Russian Federation
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
Read the detailed description
This is an observational study entailing primary and secondary data collection. As an observational, this study does not imply any intervention into a routine clinical practice, including choice of treatment modality or additional diagnostic methods. Epidemiologic methods and descriptive analysis will be used for data collection and evaluation of all endpoints and measurements of interest.
It will be a multicentre study. Planned number of study sites is about 30 oncological centres performing specialised treatment and follow-up of patients with urothelial bladder cancer in different regions of Russia. Planned study population consists of approximately 600 adult patients with urothelial bladder cancer. Patients who were diagnosed with urothelial bladder cancer and satisfy the additional eligibility criteria as assessed by the investigator will be invited to participate during routine clinical visit. Only patients who will give their written informed consent will be included. Consecutive patients included in the study will form three study cohorts of equal size (around 200 participants each) according to the stages of urothelial bladder cancer at the time of study inclusion: high-risk NMIBC, MIBC, and mBC.
The investigator will enter medical data of the enrolled patients into the electronic case report form (eCRF) from the source medical documentation. No follow-up is planned, the study will consist of only one visit carried out according to routine clinical practice, where patient's demographic and clinical characteristics as well as medical history and used treatment approaches will be recorded, and formalin-fixed paraffin-embedded (FFPE) tumour tissue samples collected as part of routine clinical practice will be shipped to the central laboratory.
The overall expected duration of the study enrollment is about 18 months or until 600 patients will be included in the study, and all required data (including results of IHC testing in central laboratory) will be collected, whichever occurs first.
- Conditions
- Bladder Cancer
- Medical subject headings
- Urinary Bladder Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with NMIBC | Non-muscle-invasive bladder cancer | |
| Patients with MIBC | Muscle-invasive bladder cancer | |
| Patients with mBC | Metastatic bladder cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients receiving any intravesical treatment among patients with high-risk NMIBC
Proportion of patients receiving any intravesical treatment among patients with high-risk Non-muscle invasive bladder cancer (ongoing and anamnestic);
Measured: 24 months
Proportion of patients receiving intravesical chemotherapy among patients with high-risk NMIBC
Proportion of patients receiving intravesical chemotherapy among patients with high-risk ongoing and anamnestic Non-muscle invasive bladder cancer (overall and by each treatment regimen);
Measured: 24 months
Proportion of patients receiving intravesical BCG treatment among patients with high-risk NMIBC
Proportion of patients receiving intravesical Bacillus Calmette-Guérin treatment among patients with high-risk ongoing and anamnestic Non-muscle-invasive bladder cancer (overall and by each treatment regimen: induction/ induction + maintenance);
Measured: 24 months
Proportion of patients receiving any intravesical treatment among patients with non-high-risk NMIBC
Proportion of patients receiving any intravesical treatment among patients with non-high-risk Non-muscle-invasive bladder cancer (anamnestic);
Measured: 24 months
Proportion of patients receiving intravesical chemotherapy among patients with non-high-risk anamnestic NMIBC
Proportion of patients receiving intravesical chemotherapy among patients with non-high-risk anamnestic Non-muscle-invasive bladder cancer (overall and by each treatment regimen);
Measured: 24 months
Proportion of patients receiving intravesical BCG treatment among patients with non high-risk anamnestic NMIBC
Proportion of patients receiving intravesical Bacillus Calmette-Guérin treatment among patients with non high-risk anamnestic Non-muscle-invasive bladder cancer(overall and by each treatment regimen: induction/ induction + maintenance);
Measured: 24 months
Proportion of patients without intravesical NMIBC treatment
Proportion of patients without intravesical Non-muscle-invasive bladder cancer (ongoing and anamnestic) treatment (high-risk, non-high-risk)
Measured: 24 months
Number of relapses in high risk NMIBC patients (ongoing and anamnestic) overall and by each treatment regimen
Number of relapses in high risk Non-muscle-invasive bladder cancer patients (ongoing and anamnestic) overall and by each treatment regimen (intravesical chemotherapy, intravesical BCG (induction or induction with maintenance))
Measured: 24 months
Number of relapses in non-high risk NMIBC patients overall and by each treatment regimen, intravesical BCG
Number of relapses in non-high risk Non-muscle-invasive bladder cancer patients (anamnestic) overall and by each treatment regimen (intravesical chemotherapy, intravesical Bacillus Calmette-Guérin (induction or induction with maintenance))
Measured: 24 months
Time to first relapse of NMIBC
Time to first relapse of NMIBC (ongoing and anamnestic)
Measured: 24 months
Proportion of patients receiving neoadjuvant treatment among patients with MIBC
Proportion of patients receiving neoadjuvant treatment among patients with Muscle-invasive bladder cancer (ongoing and anamnestic) (overall and by each treatment regimen);
Measured: 24 months
Rate of pathologic complete response among MIBC patients receiving neoadjuvant treatment
Rate of pathologic complete response among Muscle-invasive bladder cancer patients (ongoing and anamnestic) receiving neoadjuvant treatment (overall and by each treatment regimen);
Measured: 24 months
Proportion of MIBC patients not received neoadjuvant treatment before radical cystectomy
Proportion of Muscle-invasive bladder cancer patients (ongoing and anamnestic) not received neoadjuvant treatment before radical cystectomy.
Measured: 24 months
Proportion of patients received adjuvant treatment among patients with MIBC
Proportion of patients received adjuvant treatment among patients with Muscle-invasive bladder cancer (ongoing and anamnestic) (overall and by each treatment regimen);
Measured: 24 months
Proportion of MIBC patients (anamnestic) received trimodal therapy
Proportion of Muscle-invasive bladder cancer patients (anamnestic) received trimodal therapy (maximal Transurethral resection of bladder tumor + chemoradiation therapy);
Measured: 24 months
Time to progression to mBC from NMIBC and MIBC
Time to progression to metastatic bladder cancer (anamnestic) from Non-muscle-invasive bladder cancer and Muscle-invasive bladder cancer;
Measured: 24 months
Type of progression to mBC from NMIBC and MIBC
Type of progression to Metastatic bladder cancer (anamnestic) from Non-muscle-invasive bladder cancer and Muscle-invasive bladder cancer(localization of metastases);
Measured: 24 months
Proportion of patients with locoregional progression after cystectomy
Proportion of patients with locoregional progression after cystectomy (Muscle-invasive bladder cancer, anamnestic);
Measured: 24 months
Proportions of patients receiving systemic treatment regimens within first-line therapy among patients with mBC
Proportions of patients receiving systemic treatment regimens within first-line therapy among patients with Metastatic bladder cancer (by each treatment regimen);
Measured: 24 months
Proportion of patients with progression on first line mBC treatment
Proportion of patients with progression on first line Metastatic bladder cancer treatment overall and by each treatment regimen.
Measured: 24 months
Secondary outcomes (5)
Prevalence of IHC-defined HER2-positive status among patients with high-risk NMIBC
Prevalence of immunohistochemically-defined HER2-positive status (defined as proportion of patients with 3+ HER2 protein expression based on immunohistochemistry testing of formalin-fixed paraffin-embedded tumor tissue samples) among patients with high-risk Non-muscle-invasive bladder cancer;
Measured: 24 months
Prevalence of IHC-defined HER2-positive status among patients with MIBC
Prevalence of mmunohistochemically-defined HER2-positive status (defined as proportion of patients with 3+ HER2 protein expression based on immunohistochemistry testing of formalin-fixed paraffin-embedded tumour tissue samples) among patients with Muscle-invasive bladder cancer;
Measured: 24 months
Prevalence of IHC-defined HER2-positive status among patients with mBC;
Prevalence of mmunohistochemically-defined HER2-positive status (defined as proportion of patients with 3+ HER2 protein expression based on immunohistochemistry testing of formalin-fixed paraffin-embedded tumour tissue samples) among patients with mBC;
Measured: 24 months
Concordance of immunohistochemically-defined HER2-positive status among 3 patient cohorts
Concordance of immunohistochemically-defined HER2-positive status (defined as proportion of patients with 3+ HER2 protein expression based on immunohistochemistry testing of formalin-fixed paraffin-embedded tumour tissue samples) among patients with Non-muscle-invasive bladder cancer, muscle-invasive bladder cancer and metastatic bladder cancer in primary tumor samples and metastasis if both available;
Measured: 24 months
Prevalence of PD-L1 positive status among patients with mBC
Prevalence of PD-L1 positive status (defined as proportion of patients with at least one of the following criteria based on IHC testing of Formalin-fixed paraffin-embedded tumour tissue sample: (1) ≥25% PD L1 positive tumor cells; (2) ≥25% PD-L1-positive immune cells if >1% of the tumor area contained such cellular elements; or (3) 100% PD-L1-positive immune cells if 1% of the tumor area contained immune cells) among patients with metastatic bladder cancer.
Measured: 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2025
- Study start30 Jun 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bladder CancerStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07038928
- Sponsor's protocol ID
- D133HR00057
- Acronym
- RIVERS
- Status last verified
- Sep 2026
- First submitted
- 5 Jun 2025
- Last updated
- 14 Sep 2026
- Results posted
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicentre Observational Study on Treatment Approaches and HER2 Positive Status Prevalence in Different Stages of Bladder Cancer and PD-L1-positive Status in Metastatic Bladder Cancer in Russian Federation
- ClinicalTrials.gov ID
- NCT07038928
- Acronym / sponsor ID
- RIVERS / D133HR00057
- Conditions
- Bladder Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 30 Jun 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 26 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
Detailed description
This is an observational study entailing primary and secondary data collection. As an observational, this study does not imply any intervention into a routine clinical practice, including choice of treatment modality or additional diagnostic methods. Epidemiologic methods and descriptive analysis will be used for data collection and evaluation of all endpoints and measurements of interest.
It will be a multicentre study. Planned number of study sites is about 30 oncological centres performing specialised treatment and follow-up of patients with urothelial bladder cancer in different regions of Russia. Planned study population consists of approximately 600 adult patients with urothelial bladder cancer. Patients who were diagnosed with urothelial bladder cancer and satisfy the additional eligibility criteria as assessed by the investigator will be invited to participate during routine clinical visit. Only patients who will give their written informed consent will be included. Consecutive patients included in the study will form three study cohorts of equal size (around 200 participants each) according to the stages of urothelial bladder cancer at the time of study inclusion: high-risk NMIBC, MIBC, and mBC.
The investigator will enter medical data of the enrolled patients into the electronic case report form (eCRF) from the source medical documentation. No follow-up is planned, the study will consist of only one visit carried out according to routine clinical practice, where patient's demographic and clinical characteristics as well as medical history and used treatment approaches will be recorded, and formalin-fixed paraffin-embedded (FFPE) tumour tissue samples collected as part of routine clinical practice will be shipped to the central laboratory.
The overall expected duration of the study enrollment is about 18 months or until 600 patients will be included in the study, and all required data (including results of IHC testing in central laboratory) will be collected, whichever occurs first.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Patients with NMIBC | – | –Non-muscle-invasive bladder cancer |
| Patients with MIBC | – | –Muscle-invasive bladder cancer |
| Patients with mBC | – | –Metastatic bladder cancer |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Planned study population consists of approximately 600 adult patients with urothelial bladder cancer. Patients who were diagnosed with urothelial bladder cancer and satisfy the additional eligibility criteria as assessed by the investigator will be invited to participate during routine clinical visit. Only patients who will give their written informed consent will be included. Consecutive patients included in the study will form three study cohorts of equal size (around 200 participants each) according to the stages of urothelial bladder cancer at the time of study inclusion: high-risk NMIBC, MIBC, and mBC.
Key inclusion criteria (12 listed)
- Age ≥ 18 years;
- Signed ICF, including consent for FFPE tumor tissue sample testing;
- Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry;
- For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature:
- For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry;
Key exclusion criteria (1 listed)
- Participation in any interventional trial since the urothelial bladder cancer diagnosis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Proportion of patients receiving any intravesical treatment among patients with high-risk NMIBC
Time frame: 24 months
Proportion of patients receiving any intravesical treatment among patients with high-risk Non-muscle invasive bladder cancer (ongoing and anamnestic);
Proportion of patients receiving intravesical chemotherapy among patients with high-risk NMIBC
Time frame: 24 months
Proportion of patients receiving intravesical chemotherapy among patients with high-risk ongoing and anamnestic Non-muscle invasive bladder cancer (overall and by each treatment regimen);
Proportion of patients receiving intravesical BCG treatment among patients with high-risk NMIBC
Time frame: 24 months
Proportion of patients receiving intravesical Bacillus Calmette-Guérin treatment among patients with high-risk ongoing and anamnestic Non-muscle-invasive bladder cancer (overall and by each treatment regimen: induction/ induction + maintenance);
Proportion of patients receiving any intravesical treatment among patients with non-high-risk NMIBC
Time frame: 24 months
Proportion of patients receiving any intravesical treatment among patients with non-high-risk Non-muscle-invasive bladder cancer (anamnestic);
Proportion of patients receiving intravesical chemotherapy among patients with non-high-risk anamnestic NMIBC
Time frame: 24 months
Proportion of patients receiving intravesical chemotherapy among patients with non-high-risk anamnestic Non-muscle-invasive bladder cancer (overall and by each treatment regimen);
Proportion of patients receiving intravesical BCG treatment among patients with non high-risk anamnestic NMIBC
Time frame: 24 months
Proportion of patients receiving intravesical Bacillus Calmette-Guérin treatment among patients with non high-risk anamnestic Non-muscle-invasive bladder cancer(overall and by each treatment regimen: induction/ induction + maintenance);
Proportion of patients without intravesical NMIBC treatment
Time frame: 24 months
Proportion of patients without intravesical Non-muscle-invasive bladder cancer (ongoing and anamnestic) treatment (high-risk, non-high-risk)
Number of relapses in high risk NMIBC patients (ongoing and anamnestic) overall and by each treatment regimen
Time frame: 24 months
Number of relapses in high risk Non-muscle-invasive bladder cancer patients (ongoing and anamnestic) overall and by each treatment regimen (intravesical chemotherapy, intravesical BCG (induction or induction with maintenance))
Number of relapses in non-high risk NMIBC patients overall and by each treatment regimen, intravesical BCG
Time frame: 24 months
Number of relapses in non-high risk Non-muscle-invasive bladder cancer patients (anamnestic) overall and by each treatment regimen (intravesical chemotherapy, intravesical Bacillus Calmette-Guérin (induction or induction with maintenance))
Time to first relapse of NMIBC
Time frame: 24 months
Time to first relapse of NMIBC (ongoing and anamnestic)
Proportion of patients receiving neoadjuvant treatment among patients with MIBC
Time frame: 24 months
Proportion of patients receiving neoadjuvant treatment among patients with Muscle-invasive bladder cancer (ongoing and anamnestic) (overall and by each treatment regimen);
Rate of pathologic complete response among MIBC patients receiving neoadjuvant treatment
Time frame: 24 months
Rate of pathologic complete response among Muscle-invasive bladder cancer patients (ongoing and anamnestic) receiving neoadjuvant treatment (overall and by each treatment regimen);
Proportion of MIBC patients not received neoadjuvant treatment before radical cystectomy
Time frame: 24 months
Proportion of Muscle-invasive bladder cancer patients (ongoing and anamnestic) not received neoadjuvant treatment before radical cystectomy.
Proportion of patients received adjuvant treatment among patients with MIBC
Time frame: 24 months
Proportion of patients received adjuvant treatment among patients with Muscle-invasive bladder cancer (ongoing and anamnestic) (overall and by each treatment regimen);
Proportion of MIBC patients (anamnestic) received trimodal therapy
Time frame: 24 months
Proportion of Muscle-invasive bladder cancer patients (anamnestic) received trimodal therapy (maximal Transurethral resection of bladder tumor + chemoradiation therapy);
Time to progression to mBC from NMIBC and MIBC
Time frame: 24 months
Time to progression to metastatic bladder cancer (anamnestic) from Non-muscle-invasive bladder cancer and Muscle-invasive bladder cancer;
Type of progression to mBC from NMIBC and MIBC
Time frame: 24 months
Type of progression to Metastatic bladder cancer (anamnestic) from Non-muscle-invasive bladder cancer and Muscle-invasive bladder cancer(localization of metastases);
Proportion of patients with locoregional progression after cystectomy
Time frame: 24 months
Proportion of patients with locoregional progression after cystectomy (Muscle-invasive bladder cancer, anamnestic);
Proportions of patients receiving systemic treatment regimens within first-line therapy among patients with mBC
Time frame: 24 months
Proportions of patients receiving systemic treatment regimens within first-line therapy among patients with Metastatic bladder cancer (by each treatment regimen);
Proportion of patients with progression on first line mBC treatment
Time frame: 24 months
Proportion of patients with progression on first line Metastatic bladder cancer treatment overall and by each treatment regimen.
5 secondary outcomes
Prevalence of IHC-defined HER2-positive status among patients with high-risk NMIBC
Time frame: 24 months
Prevalence of IHC-defined HER2-positive status among patients with MIBC
Time frame: 24 months
Prevalence of IHC-defined HER2-positive status among patients with mBC;
Time frame: 24 months
Concordance of immunohistochemically-defined HER2-positive status among 3 patient cohorts
Time frame: 24 months
Prevalence of PD-L1 positive status among patients with mBC
Time frame: 24 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared
Related trials for Bladder Cancer
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
RecruitingPhase 3
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) and Pembrolizumab (MK-3475A) in Participants With Bladder Cancer (MK-2870-055)
Bladder Cancer
Active, not recruitingPhase 2/3
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Biliary Tract Cancer, Cholangiocarcinoma
Recruiting
Effect of Cyclic Sighing Breathing Exercise on CRBD, Pain, and Sleep Quality in Patients Undergoing TUR
Transurethral Resection of Bladder Tumor, Transurethral Resection of the Prostate (TURP)
Recruiting
The Vanguard Study: Testing a New Way to Screen for Cancer
Bladder Carcinoma, Breast Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bladder Cancer, run by AstraZeneca at 20 sites in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients receiving any intravesical treatment among patients with high-risk NMIBC (time frame: 24 months). The study lists 20 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026.